>

Investor & Media Relations


We discover and develop medicines to defeat neurodegeneration.

The science is breaking open and the time is right for an ambitious and rigorous effort to address Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. We are applying deep scientific and drug development expertise to discover effective molecular therapeutics and have engineered a proprietary technology to deliver biologic therapeutics to the brain.

With a team of experienced and passionately dedicated scientists and drug developers, we believe we can succeed in meaningfully improving the lives of patients and their families.


Recent Press Releases

Denali Therapeutics Reports First Quarter 2019 Financial Results

May 08, 2019

Read More
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights

March 12, 2019

Read More
Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for Alzheimer’s Disease

February 15, 2019

Read More
View All

Upcoming Events

Shareholder Meeting

May 30, 2019

2019 Denali Therapeutics Annual Shareholder's Meeting

Read More
More events are coming soon.
View All


Analyst Coverage

View detailed list of firms and analysts.

View Coverage

SEC Filing

View, download, and share all SEC Filing documents.

View Documents

Corporate Governance

View, download, and share Corporate Governance documents.

View Documents

FAQs

WHERE IS DENALI INCORPORATED?

Denali Therapeutics Inc. was incorporated in Delaware in October 2013

Denali Therapeutics Inc. was incorporated in Delaware in October 2013

WHERE IS DENALI’S CORPORATE HEADQUARTERS?

Denali is headquartered in South San Francisco, CA.

Denali is headquartered in South San Francisco, CA.

WHEN IS DENALI’S FISCAL YEAR-END?

Denali's fiscal year ends December 31st

Denali's fiscal year ends December 31st

WHO IS DENALI’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM?

Ernst & Young LLP is Denali's independent registered public accounting firm

Ernst & Young LLP is Denali's independent registered public accounting firm

ON WHICH EXCHANGE IS DENALI LISTED, WHAT IS THE TICKER SYMBOL, AND WHEN DID DENALI GO PUBLIC?

Denali is traded on the NASDAQ Global Select Stock Market under the ticker symbol "DNLI"

Denali initial public offering occurred on December 8, 2017

Denali is traded on the NASDAQ Global Select Stock Market under the ticker symbol "DNLI"

Denali initial public offering occurred on December 8, 2017

WHAT IS THE CUSIP NUMBER FOR DENALI'S COMMON STOCK?

24823R 105

24823R 105

WHO IS DENALI’S TRANSFER AGENT AND HOW DO I CONTACT THEM?

American Stock Transfer & Trust Company

(800) 937-5449 (Toll-free)

(718) 921-8124 (International)

info@amstock.com http://www.amstock.com/new/Inv...

American Stock Transfer & Trust Company Operations Center

6201 15th Avenue

Brooklyn, NY 11219

American Stock Transfer & Trust Company

(800) 937-5449 (Toll-free)

(718) 921-8124 (International)

info@amstock.com http://www.amstock.com/new/Inv...

American Stock Transfer & Trust Company Operations Center

6201 15th Avenue

Brooklyn, NY 11219

HOW CAN I GET A COPY OF YOUR ANNUAL REPORT OR OTHER PERIODIC REPORTS?

Electronic copies of our Annual Report and other periodic reports are available on this website. If you would like to request paper copies of the Annual Report or other periodic reports, send your request in writing to:

Denali Therapeutics Inc.

Attn: Corporate Secretary

151 Oyster Point Blvd

South San Francisco, CA 94080

Electronic copies of our Annual Report and other periodic reports are available on this website. If you would like to request paper copies of the Annual Report or other periodic reports, send your request in writing to:

Denali Therapeutics Inc.

Attn: Corporate Secretary

151 Oyster Point Blvd

South San Francisco, CA 94080

HOW DO I CONTACT DENALI WITH ADDITIONAL QUESTIONS OR INQUIRIES?

Please use the Contact form for additional questions or inquiries.

Please use the Contact form for additional questions or inquiries.

Leadership